WHO And MPP Announce First Transparent, Global, Non-Exclusive Licence For COVID-19 Technology

World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus attends a press conference organised by the Geneva Association of United Nations Correspondents (ACANU) amid the COVID-19 outbreak, caused by the novel coronavirus, on July 3, 2020 at the WHO headquarters in Geneva. Fabrice COFFRINI / POOL / AFP
File picture: World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus attends a press convention organised by the Geneva Association of United Nations Correspondents (ACANU) amid the COVID-19 outbreak, brought on by the novel coronavirus, on July 3, 2020, on the WHO headquarters in Geneva. Fabrice COFFRINI / POOL / AFP

 

WHO’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) on Wednesday finalised a licensing settlement with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody expertise.

According to a press release by the WHO, the take a look at successfully checks for the presence of anti-SARS-CoV-2 antibodies developed both in response to a COVID-19 an infection or to a vaccine.

This represents the primary clear, world, non-exclusive licence for a COVID-19 well being device, and the primary take a look at licence signed by MPP and included within the WHO Pool.

The purpose of the licence is to facilitate the speedy manufacture and commercialization of CSIC’s COVID-19 serological take a look at worldwide. The settlement covers all associated patents and the organic materials mandatory for the manufacture of the take a look at.

CSIC will present all know-how to MPP and/or to potential licensees in addition to coaching. The licence might be royalty-free for low- and middle-income nations and can stay legitimate till the date the final patent expires.

“This licence is a testament to what we can achieve when putting people at the centre of our global and multilateral efforts,” mentioned Carlos Alvarado Quesada, President of Costa Rica, the founding nation of C-TAP.

“It exhibits that solidarity and equitable entry will be achieved and that it’s worthwhile persevering with to assist the rules of transparency, inclusiveness and non-exclusivity that the C-TAP defends.

“Costa Rica welcomes the signing of this licence and is convinced, today more than ever, that mechanisms such as C-TAP can help us overcome the current situation, while being beneficial for future health crises. I thank the Spanish Government and CSIC, for taking a step forward in solidarity and prioritizing health as a global public good.”

“I highly commend CSIC, a public research institute, for its commitment to solidarity and for offering worldwide access to their technology and know-how,” mentioned Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

“This is the type of open and clear licence we have to transfer the needle on entry throughout and after the pandemic.

“I urge developers of COVID-19 vaccines, treatments and diagnostics to follow this example and turn the tide on the pandemic and on the devastating global inequity this pandemic has spotlighted.”

“Our strong partnership with WHO and C-TAP partners has been essential in negotiating this licence, and I look forward to our continued collaboration, drawing on WHO’s expertise and guidance going forward,” mentioned Charles Gore, Executive Director of MPP.

“What is clear is that MPP’s model can work across different health technologies, and we are thrilled to be signing our first C-TAP/MPP test licence with CSIC.”
Dr Rosa Menéndez, president of CSIC, emphasised how vital it’s to hunt options in order that applied sciences associated to the COVID-19 pandemic particularly, and well being on the whole, attain all nations, together with these most in want.

“In this sense, we would like this action by CSIC, of taking part in the international initiatives of MPP and WHO, to become an example and a reference for other research organizations in the world.”

The expertise up to now has resulted in 4 completely different exams, one in all which has the potential to tell apart the immune response of COVID-19 contaminated people from vaccinated people. This ought to support additional analysis into the extent and size of immunity and the efficacy of the instruments at our disposal.

The exams are easy to make use of and appropriate for all settings with a fundamental laboratory infrastructure, akin to these present in rural areas in low- and middle-income nations. The studying can theoretically be accomplished manually (with bare eye evaluating the color of the wells towards the color chart), however an ELISA reader is really useful for higher accuracy of outcomes.

Promising efficiency information within the European inhabitants will should be supplemented by the businesses that can produce this expertise in the event that they plan to promote the take a look at in low- and middle-income nations.

Leave a Reply

Your email address will not be published.

WHO And MPP Announce First Transparent, Global, Non-Exclusive Licence For COVID-19 Technology

Send this to a friend